Detailed Information

Cited 4 time in webofscience Cited 3 time in scopus
Metadata Downloads

Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B

Authors
Chon, H.Y.Seo, Y.S.Lee, J.I.Kim, B.S.Jang, B.K.Kim, S.G.Suk, K.T.Kim, I.H.Lee, J.-W.Chon, Y.E.Kim, M.Y.Jeong, S.W.Lee, H.A.Yim, S.Y.Um, S.H.Lee, H.W.Lee, K.S.Song, J.E.Lee, C.H.Chung, W.J.Hwang, J.S.Yoo, J.-J.Kim, Y.S.Kim, D.J.Lee, C.H.Yu, J.H.Ha, Y.J.Kim, M.N.Lee, J.H.Hwang, S.G.Kang, S.H.Baik, S.K.Jang, J.Y.Suh, S.J.Jung, Y.K.Kim, B.K.Park, J.Y.Kim, D.Y.Ahn, S.H.Han, K.-H.Yim, H.J.Kim, S.U.
Issue Date
Jun-2021
Publisher
Lippincott Williams and Wilkins
Keywords
antiviral therapy; chronic hepatitis B; hepatocellular carcinoma; risk prediction; transient elastography
Citation
European Journal of Gastroenterology and Hepatology, v.33, no.06, pp.885 - 893
Indexed
SCIE
SCOPUS
Journal Title
European Journal of Gastroenterology and Hepatology
Volume
33
Number
06
Start Page
885
End Page
893
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/53019
DOI
10.1097/MEG.0000000000001794
ISSN
0954-691X
Abstract
Objective The liver stiffness-based risk prediction models predict hepatocellular carcinoma (HCC) development. We investigated the influence of antiviral therapy (AVT) on liver stiffness-based risk prediction model in patients with chronic hepatitis B (CHB). Methods Patients with CHB who initiated AVT were retrospectively recruited from 13 referral Korean institutes. The modified risk estimation for hepatocellular carcinoma in chronic hepatitis B (mREACH-B) model was selected for the analysis. Results Between 2007 and 2015, 1034 patients with CHB were recruited. The mean age of the study population (639 men and 395 women) was 46.8 years. During AVT, the mREACH-B score significantly decreased from the baseline to 3 years of AVT (mean 9.21 → 7.46, P < 0.05) and was maintained until 5 years of AVT (mean 7.23, P > 0.05). The proportion of high-risk patients (mREACH-B score ≥11) was significantly reduced from the baseline to 2 years of AVT (36.4% → 16.4%, P < 0.001) and was maintained until 5 years of AVT (12.2%, P > 0.05). The mREACH-B scores at baseline and 1 year of AVT independently predicted HCC development (hazard ratio = 1.209-1.224) (all P < 0.05). The cumulative incidence rate of HCC was significantly different at 5 years of AVT among risk groups (high vs. high-intermediate vs. low-intermediate vs. low) from baseline (4.5% vs. 3.2% vs. 1.5% vs. 0.8%) and 1 year (11.8% vs. 4.6% vs. 1.8% vs. 0.6%) (all P < 0.05, log-rank tests). Conclusions The mREACH-B score was dynamically changed during AVT. Thus, repeated assessment of the mREACH-B score is required to predict the changing risk of HCC development in patients with CHB undergoing AVT. © 2021 Lippincott Williams and Wilkins. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE